Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Cu-AKY-2519

Radiopharmaceutical · Acts on B7-H3 (CD276) · developed by Aktis Oncology

Phase 1 Most advanced trial
AKTS Developer
1 Registered trials

What is Cu-AKY-2519?

Cu-AKY-2519 is a copper-64 labeled radiopharmaceutical used for imaging in metastatic castration-resistant prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Radiopharmaceutical
Targets
B7-H3 (CD276) (biomarker)
Mechanism
Acts on B7-H3 (CD276)
Therapy area
Oncology
Developer
Aktis Oncology, Inc. (AKTS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07581184 Phase 1 Castration Resistant Metastatic Prostate Cancer Recruiting AKTS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

B7H3Castration Resistant Metastatic Prostate CancermCRPCmCRPC (Metastatic Castration-resistant Prostate Cancer)Prostate Cancer

Other drugs acting on CD276

Ac-AKY-2519 Phase 1 GTB-5550 Phase 1 Ifinatamab Deruxtecan Phase 2

More from Aktis Oncology

Ac-AKY-1189 Phase 1 Ac-AKY-2519 Phase 1 Cu-AKY-1189 Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the AKTS page.

Follow AKTS, the company behind Cu-AKY-2519

See AKTS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AKTS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.